Aura Biosciences Inc

Company Profile

Aura Biosciences Inc had its IPO on 2021-10-29 under the ticker symbol AURA.

The company operates in the Healthcare sector and Biotechnology industry. Aura Biosciences Inc has a staff strength of 70 employees.

Stock update

Shares of Aura Biosciences Inc opened at $10.33 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $9.99 - $10.37, and closed at $10.21.

This is a -1.07% slip from the previous day's closing price.

A total volume of 48,964 shares were traded at the close of the day’s session.

In the last one week, shares of Aura Biosciences Inc have slipped by -2.2%.

Aura Biosciences Inc's Key Ratios

Aura Biosciences Inc has a market cap of $461.16 million, indicating a price to book ratio of 3.8729 and a price to sales ratio of 0.

In the last 12-months Aura Biosciences Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-65679000. The EBITDA ratio measures Aura Biosciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Aura Biosciences Inc’s operating margin was 0% while its return on assets stood at -23.74% with a return of equity of -39.46%.

In Q1, Aura Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Aura Biosciences Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aura Biosciences Inc’s profitability.

Aura Biosciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -6.6724. Its price to sales ratio in the trailing 12-months stood at 0.

Aura Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$206.02 million

Total Liabilities

$8.11 million

Operating Cash Flow

$-66879000.00

Capital Expenditure

$109000

Dividend Payout Ratio

0%

Aura Biosciences Inc ended 2024 with $206.02 million in total assets and $0 in total liabilities. Its intangible assets were valued at $206.02 million while shareholder equity stood at $180.26 million.

Aura Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $8.11 million in other current liabilities, in common stock, $-228366000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $38.49 million and cash and short-term investments were $173.52 million. The company’s total short-term debt was $2,985,000 while long-term debt stood at $0.

Aura Biosciences Inc’s total current assets stands at $179.12 million while long-term investments were $0 and short-term investments were $135.03 million. Its net receivables were $0 compared to accounts payable of $1.06 million and inventory worth $0.

In 2024, Aura Biosciences Inc's operating cash flow was $-66879000.00 while its capital expenditure stood at $109000.

Comparatively, Aura Biosciences Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$10.21

52-Week High

$24.83

52-Week Low

$8.13

Analyst Target Price

$30.67

Aura Biosciences Inc stock is currently trading at $10.21 per share. It touched a 52-week high of $24.83 and a 52-week low of $24.83. Analysts tracking the stock have a 12-month average target price of $30.67.

Its 50-day moving average was $11.1 and 200-day moving average was $10.89 The short ratio stood at 24.07 indicating a short percent outstanding of 0%.

Around 826.8% of the company’s stock are held by insiders while 7386.5% are held by institutions.